Artivion, Inc. (NYSE:AORT) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Artivion, Inc. (NYSE:AORT) have received a consensus rating of “Moderate Buy” from the eight ratings firms that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $50.4667.

A number of analysts have recently commented on AORT shares. Stifel Nicolaus set a $55.00 price target on Artivion in a research note on Thursday. Wall Street Zen downgraded shares of Artivion from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Weiss Ratings upgraded shares of Artivion from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, February 20th. Canaccord Genuity Group decreased their price target on shares of Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a report on Friday, February 13th. Finally, Needham & Company LLC restated a “buy” rating and issued a $58.00 price objective on shares of Artivion in a research report on Monday, February 2nd.

Artivion Stock Performance

AORT stock opened at $37.18 on Tuesday. Artivion has a twelve month low of $21.97 and a twelve month high of $48.25. The company has a quick ratio of 2.62, a current ratio of 3.53 and a debt-to-equity ratio of 0.49. The company has a market cap of $1.78 billion, a P/E ratio of 185.91 and a beta of 1.60. The business’s fifty day moving average is $41.06 and its 200-day moving average is $42.85.

Artivion (NYSE:AORT) last announced its quarterly earnings data on Thursday, February 12th. The company reported $0.17 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.03. Artivion had a return on equity of 7.43% and a net margin of 2.21%.The business had revenue of $118.30 million during the quarter, compared to analysts’ expectations of $116.42 million. Artivion’s revenue for the quarter was up 19.2% on a year-over-year basis. Equities research analysts forecast that Artivion will post 0.37 EPS for the current year.

Insider Activity at Artivion

In other Artivion news, insider John E. Davis sold 4,573 shares of the firm’s stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $37.78, for a total transaction of $172,767.94. Following the sale, the insider directly owned 230,794 shares in the company, valued at approximately $8,719,397.32. This trade represents a 1.94% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Lance A. Berry sold 6,316 shares of Artivion stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $37.78, for a total transaction of $238,618.48. Following the completion of the transaction, the executive vice president directly owned 210,827 shares in the company, valued at approximately $7,965,044.06. The trade was a 2.91% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 137,615 shares of company stock valued at $5,180,246 over the last 90 days. Insiders own 7.60% of the company’s stock.

Institutional Investors Weigh In On Artivion

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd acquired a new position in shares of Artivion during the third quarter worth about $27,000. Aster Capital Management DIFC Ltd lifted its stake in Artivion by 402.3% in the 3rd quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock valued at $27,000 after acquiring an additional 519 shares in the last quarter. Larson Financial Group LLC lifted its stake in Artivion by 148.5% in the 4th quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock valued at $43,000 after acquiring an additional 563 shares in the last quarter. USA Financial Formulas boosted its position in Artivion by 163.5% during the 4th quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock worth $52,000 after acquiring an additional 703 shares during the last quarter. Finally, KBC Group NV bought a new position in shares of Artivion during the 4th quarter worth approximately $65,000. 86.37% of the stock is currently owned by institutional investors and hedge funds.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.